Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F E De Jongh

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
The Netherlands Journal of Medicine|November 8, 2011
A rare cause of abdominal pain. Epiploic appendagitisK E Verweij, F E de Jongh
BMJ Case Reports|March 3, 2016
Lethal acute liver failure in a patient treated with sunitinibS S Guillen, M Meijer, F E de Jongh
Nederlands Tijdschrift Voor Geneeskunde|January 6, 1996
[Acute pancreatitis caused by metronidazole]F E de Jongh, J P Ottervanger, P C Stuiver
European Journal of Endocrinology|March 15, 2001
Thyroid morphology in lethal non-thyroidal illness: a post-mortem studyF E De Jongh, A C Jöbsis, J W Elte
Anti-Cancer Drugs|July 11, 2003
Cisplatin-induced encephalopathy and seizuresN Steeghs, F E de Jongh, P A E Sillevis Smitt, et al.
The American Journal of Gastroenterology|August 1, 1991
Prognostic implications of the localization of carcinoma in the head of the pancreasG A Nix, C Dubbelman, E D Srivastava, et al.
Gastroenterology|November 1, 1992
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liverF E de Jongh, H L Janssen, R A de Man, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2002
Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancerF E de Jongh, R de Wit, J Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposureF E de Jongh, J Verweij, W J Loos, et al.
British Journal of Cancer|April 17, 2003
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patientsF E de Jongh, R N van Veen, S J Veltman, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
The Netherlands Journal of Medicine|November 8, 2011
A rare cause of abdominal pain. Epiploic appendagitisK E Verweij, F E de Jongh
BMJ Case Reports|March 3, 2016
Lethal acute liver failure in a patient treated with sunitinibS S Guillen, M Meijer, F E de Jongh
Nederlands Tijdschrift Voor Geneeskunde|January 6, 1996
[Acute pancreatitis caused by metronidazole]F E de Jongh, J P Ottervanger, P C Stuiver
European Journal of Endocrinology|March 15, 2001
Thyroid morphology in lethal non-thyroidal illness: a post-mortem studyF E De Jongh, A C Jöbsis, J W Elte
Anti-Cancer Drugs|July 11, 2003
Cisplatin-induced encephalopathy and seizuresN Steeghs, F E de Jongh, P A E Sillevis Smitt, et al.
The American Journal of Gastroenterology|August 1, 1991
Prognostic implications of the localization of carcinoma in the head of the pancreasG A Nix, C Dubbelman, E D Srivastava, et al.
Gastroenterology|November 1, 1992
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liverF E de Jongh, H L Janssen, R A de Man, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2002
Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancerF E de Jongh, R de Wit, J Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposureF E de Jongh, J Verweij, W J Loos, et al.
British Journal of Cancer|April 17, 2003
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patientsF E de Jongh, R N van Veen, S J Veltman, et al.
Pageof 2